Search
for
Sort by
Research 181–210 of 1000+
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Review of the Literature: Topical JAK Inhibitors Showing Promise for Hair Loss!
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Baricitinib for alopecia areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Alopecia Areata: A Complex Cytokine Driven Disease
- APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Janus Kinase inhibitors in dermatology: a review
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- The JAK/STAT signaling pathway: from bench to clinic
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
- Alopecia areata
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata